The companies anticipate finalising the acquisition in the third quarter of 2026.
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease.
As the first-to-market DPP-1 inhibitor, Brinsupri is on course to become the standard of care in bronchiectasis treatment.
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
The new application was based on results from the Phase III SCOUT-HCM trial.
